Recent surveillance efforts have unveiled a disturbing escalation in the occurrence of carbapenemase-producing organisms (CPOs) in Ontario’s hospitals. Over the span of a mere year, from 2022 to 2023, these antibiotic-resistant pathogens have amplified twofold, according to a current report issued by Public Health Ontario.
Their statewide survey, distributed to public hospitals and microbiology laboratories, identified that 1,229 patients were colonized or infected by a CPO in 2023, representing a striking increase from 560 the prior year. When adjusted for hospital size, the elevated risk of new patients carrying CPOs doubled from a mere 5.1 to a substantial 10.2 per 10,000 patients. Worryingly, 98.2% of these newfound CPO cases were colonized or infected by the Enterobacteriaceae family of bacteria.
Dissecting the types of carbapenemase present, the New Delhi Metallo-beta-lactamase enzyme was the most prevalent (55.2%), trailed by Oxacillinase (26.0%) and Klebsiella pneumoniae carbapenemase (13.7%). In addition to this escalation, laboratory reports revealed heightened resistance to third-generation cephalosporins in Escherichia coli and Klebsiella pneumoniae populations. Moreover, a mounting resistance to ciprofloxacin among E coli isolates was reported, reaching 22.3% in 2023, marking the highest resistance rates observed to date.
However, it’s not all bad news. The survey noted a 17.5% decline in new infections with methicillin-resistant Staphylococcus aureus (MRSA) compared to the previous year and a reduction in the positivity rate for Clostridioides difficile (from 12.1% in 2022 to 10.1% in 2023).
The public health teams underscored the critical role of the epidemiological data extracted from Ontario laboratories and healthcare facilities’ infection prevention and control programs. These statistics not only aid in understanding the impacts of antimicrobial-resistant organisms (AROs) but they also help shape recommendations to curb their spread within the province. Continuous and enhanced surveillance is essential to comprehend the current landscape of resistance.
Digging into different stories in infectious disease prevention, other noteworthy news includes new H5N1 avian flu confirmations that have impacted more extensive poultry farms in four US states, including Ohio. This disease has led to the loss of nearly 19 million birds over the last 30 days.
Saudi Arabia’s recent substantial financial commitment of $500 million to eradicate global polio was also announced at the fourth Riyadh International Humanitarian Forum. This commitment will help vaccinate 370 million children annually to halt the transmission of the polio virus in Pakistan and Afghanistan, among other areas.
Closer to home, a study conducted in Ohio revealed that despite their current low prevalence, infections with macrolide-resistant Mycoplasma pneumoniae are rising amidst the unfolding COVID-19 pandemic. This surge emphasizes the urgent need for ongoing surveillance and awareness of antimicrobial resistance to support effective patient management.